NTRA Natera, Inc. Insider Trading

Executive Chairman Rabinowitz sells ~7,708 shares across five transactions; stock near 52-week lows following sustained gains.

Matthew Rabinowitz, Executive Chairman of Natera, executed a series of sales totaling approximately 7,708 shares between May 4 and May 5, representing meaningful portfolio activity for an officer with direct operational knowledge. The timing coincides with the stock trading significantly below its 52-week high, suggesting he is not selling into momentum. Rabinowitz's track record consists entirely of prior sales—twenty consecutive sell transactions with no record of purchases—yet those prior sales have demonstrated poor exit timing, with the stock subsequently appreciating after each prior sale. Against this backdrop of unsuccessful timing on prior exits, he is again selling, now when the company remains unprofitable despite substantial revenue growth. The combination of repeated selling by someone with operational knowledge, coupled with his demonstrated inability to time exits well in this stock previously, creates a conflicting signal: his consistent selling behavior suggests caution about the company's direction, but his poor historical timing implies skepticism about his ability to identify the right selling opportunities.

President of Clinical Diagnostics sells $693,560 in Natera stock, continuing a 102-trade pattern of open-market dispositions with poor historical timing.

Moshkevich Solomon, President of Clinical Diagnostics at Natera, sold approximately $694,000 in shares across seven tranches in a single day, reducing his holding by less than 2.5 percent. This filing continues an extreme pattern: across a 36-month window, Solomon has executed 102 open-market sales and zero open-market purchases—pure selling with no buying activity whatsoever. At this specific ticker, his five prior sales were uniformly poorly timed, with the stock rising after each exit, suggesting he has not successfully predicted price movements in Natera stock historically. The company remains unprofitable despite strong revenue growth, and the stock currently trades well below its 52-week high. While the sale itself is modest relative to his holdings, the relentless execution of sell-only activity by someone in operational leadership over three years, combined with a track record of selling into subsequent rallies, warrants attention as a potential signal of sustained insider skepticism about near-term prospects.